Key result
Vitamin K antagonist use in low-risk atrial fibrillation patients was associated with significantly higher median coronary artery calcium scores compared to non-users (29 vs 0; P=0.001).
Why the study?
Does chronic vitamin K antagonist use increase coronary artery calcification in low-risk atrial fibrillation patients?
Observational (n=157)
Does chronic vitamin K antagonist use increase coronary artery calcification in low-risk atrial fibrillation patients?
Absolute Event Rate: 29% vs 0%
p-value: p=0.001
Vitamin K antagonist use in low-risk atrial fibrillation patients is independently associated with increased coronary artery calcification, with higher scores observed with longer duration of therapy.
No takes yet. Share an insight, caveat, or question.
No practice change for VKA in low-risk AF; leaves open whether use promotes coronary calcification.
Weijs et al. (2011) conducted an observational in Atrial fibrillation (n=157). Vitamin K antagonists (VKA) vs. No VKA treatment was evaluated on Median coronary artery calcium score (p=0.001). Vitamin K antagonist use in low-risk atrial fibrillation patients was associated with significantly higher median coronary artery calcium scores compared to non-users (29 vs 0; P=0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: